Study Title
A Phase 1 Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Study Details
Description:
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of JNJ-69086420 in Part 1 (Dose Escalation) and to determine safety and and preliminary signs of clinical activity at the RP2D(s) in Part 2 (Dose Expansion).
Sponsor:
Janssen Pharmaceuticals
Contacts:
Study Contactparticipate-in-this-study@its.jnj.com
844-434-4210
Government Study Link:
NCT04644770 - Click here to see study onClinicalTrials.gov